Prevalence of metabolic syndrome in a hemodialysis population

The role of metabolic syndrome [MS] in hemodialysis population has not been thoroughly studied. This study aimed to determine the prevalence of MS and to identify its correlates among hemodialysis patients. This cross-sectional study was conducted on patients in a hemodialysis center. The MS was defined according the Adult Treatment Panel III criteria. Clinical data of the patients were collected and blood samples were studied to measure fasting blood glucose and lipid profile. Eighty hemodialysis patients, including 47 men [58.8%] and 33 women [41.2%] with a mean age of 55.6 +/- 15.6 years, were enrolled in this study. Metabolic syndrome was diagnosed in 23 patients [28.7%]. Hypertension was present in 55 patients [68.8%]. Fifteen patients [18.8%] were diabetic, 24 [30.0%]] had a high serum triglyceride, 22 [27.5%] had a low high-density lipoprotein cholesterol, and 20 [25.0%] had evidence of abdominal obesity. Patients with MS had significantly higher body mass indexes [P < .001], fasting blood glucose levels [P < .001], and triglyceride levels [P = .004]. Metabolic syndrome was not associated with gender, age, and duration of hemodialysis. Men showed significant abnormality in glucose metabolism [P = .008]. Prevalence of low high-density lipoprotein cholesterol was significantly higher in the women than in the men [P = .02]. The prevalence of MS in our hemodialysis patients was relatively high, with the most common element being hypertension. We suggest that there needs to be a new set of criteria defined for MS in hemodialysis patients

Outcome of kidney transplantation in type 1 and type 2 diabetic patients and recipients with posttransplant diabetes mellitus

We aimed to assess the effects of different types of diabetes mellitus [DM] on patients receiving living donor kidney allografts. A total of 111 kidney transplant patients with DM and 111 randomly selected kidney transplant recipients without DM were enrolled in the study. The characteristics of the kidney allograft recipients and the allograft and patient outcomes were assessed and compared between 4 groups of kidney recipients without DM and patients with type 1 DM, type 2 DM, and posttransplant DM. Of the 111 patients with DM, 36 [32.4%], 20 [18.0%], and 55 [49.6%] had been diagnosed with type 1 DM, type 2 DM, and posttransplant DM, respectively. Diabetic patients had significantly higher rates of rejection episodes [P = .049] and suffered more frequently from delayed graft function [P = .03] compared to the kidney recipients in the control group. Patient and allograft survival rates were significantly lower in the patients with DM [regardless of their DM type] compared to the nondiabetic patients [P = .03 and P = .04, respectively]. Prominently, type 1 DM had significantly adverse effects on patient and allograft survival. Patients with posttransplant DM had a relatively better patient survival compared to those with type 1 DM and type 2 DM. We found that kidney recipients with DM, especially preexisting DM, had worse patient and graft survival rates compared to the nondiabetics. These findings suggest that kidney transplant patients presenting with any type of DM should be more closely followed